Effect of Ezetimibe on visceral fat suppression in patients with chronic liver disease and hyperlipidemia ; a randomized, double blind, placebo-controlled, clinical trial

Effect of Ezetimibe on visceral fat suppression in patients with chronic liver disease and hyperlipidemia ; a randomized, double blind, placebo-controlled, clinical trial - Effect of Ezetibmibe on viceral fat suppression in patients with chronic liver disease and hyperlipidemia.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005540

Enrollment

Registered

2011-05-02

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liver disease with hyperlipidemia

Interventions

Subjects will be assigned randomly to Ezetimibe treated group. Subjects will be received one capsule(Ezetimibe 10mg/day, and Lactose) once a day for 12weeks. Subjects will be assinged randomly to pl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Outpatients with chronic liver disease over the age of 20 in our hospital. 2.BMI 22.5kg/m2 or more. 3.Patients We obtained written informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: 1.Subjects during pregnancy, feeding, intimation of pregnancy or intended pregnancy 2.Subjects who have already treated with interferon and ribavirin 3.Subjects who have already treated with steroids, immunosuppressive agent, and antitumor agent. 4.Other,Subjects deemed unsuitable for the doctor

Design outcomes

Primary

Measure	Time frame
The change in visceral fat (measured by helical CT scan)	—

Secondary

Measure	Time frame
1)The change in serum viral genome every four weeks 2)The change in serum lipid or lipid marker levels 3)The change in serum ALT 4)The analysis of Liver tissue and lipid marker level	—

Countries

Japan

Contacts

Public ContactAkito Nozaki

Yokohama City University Medical Center Gastroenterological Center

045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026